Price Alert

Akebia Therapeutics Inc. (AKBA)

NASDAQ: AKBA · Real-Time Price · USD

3.24

-0.05 (-1.52%)

At close: Aug 15, 2025, 3:59 PM

3.25

0.31%

After-hours: Aug 15, 2025, 07:55 PM EDT

Akebia Therapeutics Statistics

Share Statistics

Akebia Therapeutics has 262.64M shares outstanding. The number of shares has increased by 24.89% in one year.

Shares Outstanding	262.64M
Shares Change (YoY)	24.89%
Shares Change (QoQ)	0.54%
Owned by Institutions (%)	40.53%
Shares Floating	254.02M
Failed to Deliver (FTD) Shares	6,830
FTD / Avg. Volume	0.14%

Short Selling Information

The latest short interest is 25.37M, so 9.66% of the outstanding shares have been sold short.

Short Interest	25.37M
Short % of Shares Out	9.66%
Short % of Float	9.76%
Short Ratio (days to cover)	7.35

Valuation Ratios

The PE ratio is -5.77 and the forward PE ratio is 37.83. Akebia Therapeutics's PEG ratio is -0.32.

PE Ratio	-5.77
Forward PE	37.83
PS Ratio	2.5
Forward PS	3.1
PB Ratio	-8.15
P/FCF Ratio	-9.85
PEG Ratio	-0.32

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Akebia Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.41, with a Debt / Equity ratio of -0.97.

Current Ratio	1.41
Quick Ratio	1.21
Debt / Equity	-0.97
Debt / EBITDA	-3.47
Debt / FCF	-1.17
Interest Coverage	-2.78

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$884.97K
Profits Per Employee	$-383.48K
Employee Count	181
Asset Turnover	0.73
Inventory Turnover	3.89

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 172.36% in the last 52 weeks. The beta is 0.96, so Akebia Therapeutics's price volatility has been higher than the market average.

Beta	0.96
52-Week Price Change	172.36%
50-Day Moving Average	3.67
200-Day Moving Average	2.45
Relative Strength Index (RSI)	44.18
Average Volume (20 Days)	4,871,461

Income Statement

In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.

Revenue	160.18M
Gross Profit	97M
Operating Income	-50.47M
Net Income	-69.41M
EBITDA	-13.72M
EBIT	-51.23M
Earnings Per Share (EPS)	-0.33

Full Income Statement

Balance Sheet

The company has 51.87M in cash and 47.64M in debt, giving a net cash position of 4.23M.

Cash & Cash Equivalents	51.87M
Total Debt	47.64M
Net Cash	4.23M
Retained Earnings	-1.68B
Total Assets	310.19M
Working Capital	112.56M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -40.66M and capital expenditures -33K, giving a free cash flow of -40.69M.

Operating Cash Flow	-40.66M
Capital Expenditures	-33K
Free Cash Flow	-40.69M
FCF Per Share	-0.19

Full Cash Flow Statement

Margins

Gross margin is 60.56%, with operating and profit margins of -31.51% and -43.33%.

Gross Margin	60.56%
Operating Margin	-31.51%
Pretax Margin	-43.33%
Profit Margin	-43.33%
EBITDA Margin	-8.57%
EBIT Margin	-31.51%
FCF Margin	-25.4%

Dividends & Yields

AKBA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AKBA is $6.5, which is 94% higher than the current price. The consensus rating is "Buy".

Price Target	$6.5
Price Target Difference	94%
Analyst Consensus	Buy
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-4.85
Piotroski F-Score	4